Loading
A phase 1/2 trial of Darovasertib, Binimetinib, Crizotinib in melanoma and uveal melanoma, run by IDEAYA Biosciences, now recruiting.
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions is a phase 1/2 interventional study registered as NCT03947385 by IDEAYA Biosciences, with 336 participants planned, started 2019-06-28 and due to reach its primary completion in 2027-01-29. Interventions recorded: IDE196, Binimetinib, Crizotinib. Conditions listed: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors. No results are recorded here; the registry entry is the source.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma, Melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Uveal melanoma.
Shares Darovasertib, IDEAYA Biosciences, Crizotinib, Uveal melanoma.
Shares Darovasertib, Uveal melanoma, Melanoma.
Shares GNAQ, Uveal melanoma.
Shares Uveal melanoma, Melanoma, Colorectal cancer.
Shares Uveal melanoma, Melanoma.